Pharmacokinetic Study of Intranasal RX0041-002 in Hepatic-Impaired Individuals and Subjects With Normal Hepatic Function
Status:
Completed
Trial end date:
2016-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the potential effect of hepatic impairment
on the systemic pharmacokinetics of RX0041-002 following single dose intranasal
administration. The secondary objective is to evaluate the safety and tolerability of
intranasal RX0041-002 in subjects with normal hepatic function and hepatic impairment.